I suspect they will share the development costs and profits evenly as 50/50 partners and that AMBS will get an upfront payment. The 250k loan is a strong indicator that they are expecting some funds in the near future and that the 250k was to get them though the near term. Considering they paid about 11 million for ESS last year, I think anything less than 5.5 million would be a huge disappointment and anything over 11 million would be really great.

Although GC has been a huge disappointment to shareholders, a potential partner will only look at what ESS is actually worth. Jason Napadano thought it was worth about 30 million when they first bought it last year. Obviously it's worth a lot more than that if successful in trials.

The biggest naysayers at this point are the same people who thought AMBS was a good investment at $7+, lost all of their money and are angry (and rightfully so) but that doesn't change what the value of ESS is.